Clofarabine, Gemcitabine and Busulfan Followed by Allogeneic Stem Cell Transplantation for Chronic Lymphocytic Leukemia (CLL)

Trial Profile

Clofarabine, Gemcitabine and Busulfan Followed by Allogeneic Stem Cell Transplantation for Chronic Lymphocytic Leukemia (CLL)

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 03 Jun 2017

At a glance

  • Drugs Gemcitabine (Primary) ; Antithymocyte globulin; Busulfan; Clofarabine; Filgrastim; Methotrexate; Tacrolimus
  • Indications Chronic lymphocytic leukaemia
  • Focus Adverse reactions
  • Most Recent Events

    • 14 Jun 2016 Planned primary completion date changed from 1 Nov 2017 to 1 Nov 2018.
    • 23 Nov 2012 Status changed from not yet recruiting to recruiting as reported by M.D. Anderson Cancer Center.
    • 23 Nov 2012 New source identified and integrated (M.D. Anderson Cancer Center).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top